A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term.
The study, whose findings were published in the journal Neuroepidemiology, analyzed a national database of more than 20,000 patients who had been treated for traumatic brain injury over a period of 37 years (1987–2024).
The investigators were especially interested in finding out how a history of TBI impacted mortality risk in brain cancer, and not just how TBIs contributed to brain cancer risk. This was the first such study on the subject. Prior studies had established links between TBI and brain cancer but hadn’t gone as far as looking into how TBI impacted brain cancer mortality.
The analysis revealed that individuals who suffered TBI due to gunshot wounds had a 14 times higher chance of dying due to brain cancer when compared to individuals whose TBI was attributed to other causes. Note that the patients included in this study were all civilians, so this finding is significant.
Additionally, the team found that individuals found to have suffered “mild but complicated” traumatic brain injuries had a fourfold increase in their risk of dying from brain cancer.
The investigators think that the trauma suffered by the brain triggers a biological cascade that includes metabolic dysregulation and persistent inflammation in the patient’s neural networks. This cascade creates favorable conditions for tumor formation, the researchers suggest.
The findings make a strong case for rethinking how TBI is managed. They call for looking at TBI as a chronic condition that goes beyond the immediate care that patients require after they have suffered the injury. TBIs should be looked at as events that have progressive oncological and neurological implications, and patients need to be monitored for the rest of their lives.
As such long-term monitoring is conducted, brain cancers and other neurological conditions can be caught early and promptly addressed. The researchers also plan on investigating how behavioral, biological and environmental factors interact to cause neurological conditions like ALS after someone has suffered a TBI.
As more studies are conducted to uncover the complex relationships between variables like TBI and brain malignancies, it is becoming clearer to drug development firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that it may be necessary to keep in mind the underlying drivers that trigger the onset of different brain cancers while seeking to bring to market effective treatments.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
